You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced Assessment to Accelerate Diagnostic Skill Acquisition

    SBC: Parallel Consulting, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Current approaches to medical education produce new physicians with insufficient clinical competency to practice effectively with limited supervision, which has serious implications for patient outcomes during hospitaloff hours. Up to 70% of patients admitted to a hospital are admitted on nights or weekends, when staffing is low and residents may be in charge o ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Advancing Formulation of STING agonist for Universal Flu Vaccine

    SBC: IMMvention Therapeutix, Inc.            Topic: NIAID

    Summary Influenza virusa member of the orthomyxovirus familyhas three different types that infect humansABand CTypes A and B produce annual epidemicsand type A influenzawhich resides asymptomatically in birdscan cause pandemic infections in humansIn addition to common flu like symptomse gfeverchillsmalaisemuscle painin susceptible populations influenza can induce potentially fatal secondary compli ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Amelioration of rhinovirus induced asthma exacerbations by serpin B1

    SBC: SERPLUS TECHNOLOGY LLC            Topic: NIAID

    PROJECT SUMMARY Asthma exacerbations are a major cause of ER visits and hospitalizations with annual direct costs of approximately $billionyear in the USAViral infectionsin particular rhinoviralRVinfectionsare a major precipitant of asthma exacerbations in allergic asthmaticsAs there are overRV serotypes andfor nowno RV vaccinenovel strategies to inhibit RV induced airway inflammation are needed t ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A molecularly targeted pre- and post-exposure vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A momentum-enabled treadling methodology to improve gait and enhance mobility in patients with peripheral arterial disease

    SBC: TREADWELL CORPORATION            Topic: NIA

    Project SummaryA significant cause of mobility impairment in the elderly is peripheral arterial diseasePADPAD results in significant functional declinereduced walking speed and distanceand lower physical activity levelsresulting in a loss of independence and impaired quality of lifeThe most effective therapy for PAD is rigorous exercisee gwalkingHowevermost PAD patients will not participate in sup ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government